Yat Sun Or sold $21k of ENTA
Chief Scientific Officer at ENANTA PHARMACEUTICALS INC. 2,591 shares at an average of $8.06, traded Dec 6, 2024, filed Dec 10, 2024.
Score components
- +15RoleOfficer
- 0Trade size$21k at market
- 0Share of holdings soldSold 0.7% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-24-020380, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2024 | SOpen-market sale Common Stock10b5-1 | -2,591 | $8.06 | $21k | 369,109 | Dec 10, 2024 |
Related signals
Other insiders at ENANTA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | ENTAbuy ENANTA PHARMACEUTICALS INC | Jay R. Luly President and CEO | $256k 45,000 shares | +6% | |
| 26Weak | ENANTA PHARMACEUTICALS INC | Jay R. Luly President and CEO | $41k 5,142 shares | -1% | |
| 17Weak | ENANTA PHARMACEUTICALS INC | Paul J Mellett Chief Fin. & Admin Officer | $21k 2,591 shares | -3% | |
| 10Weak | ENANTA PHARMACEUTICALS INC | Scott T. Rottinghaus Chief Medical Officer | $6,980 866 shares | -5% | |
| 10Weak | ENANTA PHARMACEUTICALS INC | Brendan Luu Chief Business Officer | $18k 2,283 shares | -6% | |
| 10Weak | ENANTA PHARMACEUTICALS INC | Tara Lynn Kieffer Chief Product Strategy Officer | $18k 2,283 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.